6A – 2019 IVC, Antioxidant – Chemo and Radiation Update

[gdlr_button href=”https://www.consultdranderson.com/wp-content/uploads/securepdfs/2019/10/6A-2019-IVC-Antioxidants-Chemo-and-Radiation-Update.pdf” target=”_blank” size=”large” background=”#ed4b2f” color=”#ffffff”]Download PDF[/gdlr_button]

For whatever reasons this gem of an old paper is making a resurgence at many oncologists offices and being used as a justification to not start IVC, HDIVC etc. In short (abridged below) it says:

Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O’Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res. 2008 Oct 1;68(19):8031-8. doi: 10.1158/0008-5472.CAN-08-1490. PMID: 18829561

Abstract: Vitamin C is an antioxidant vitamin that has been hypothesized to antagonize the effects of reactive oxygen species-generating antineoplastic drugs. — TRUNCATED — These findings indicate that vitamin C given before mechanisticallydissimilar antineoplastic agents antagonizes therapeutic efficacy in a model of human hematopoietic cancers by preserving mitochondrial membrane potential. These results support the hypothesis that vitamin C supplementation during cancer treatment may detrimentally affect therapeutic response.

Comment: (A) it’s 2008 and much is published in opposition since then, see below. (B) It used dehydroascorbate (DHA) which isn’t really analogous to the effects of a post infusion low or high dose IVC and (C) it is a cell line study.


Below are a few recent links which are not only more relevant but essentially make this old paper a non-issue for patients:


There are more but this group is recent, peer reviewed and supportive.

Leave a Comment

Scroll to Top